The Role of Anti‐Phosphatidylserine/Prothrombin Antibodies and the Lectin Complement Pathway in Anti‐Phospholipid Antibody‐Associated Preterm Delivery

Study limitation reported by the research below: “The aPL-negative control group is clinically heterogeneous (SLE, RA, UCTD), which may confound complement pathway comparisons.”